💯 NASDAQ: NMTC could go Viral Today!

View online

UNSUBSCRIBE NEW ALERT: ** NASDAQ: NMTC ** Alright!! Before I get to the full report on our New Alert NASDAQ: NMTC let me start by saying that this one has been announcing some MAJOR News Events in August and the stock just keeps trending UP everytime! Now the News is just one positive thing, what about all these indicators from Investing. com.. Let me show you... On Investing .com for the five hour analysis it's showing "STRONG BUY" with 12 Moving Average Indicators as a BUY and 0 as Sell!  For the Technical Indicators it shows 9 as a BUY and 0 as Sell! See the image below for yourself: With Major Wall Street Interest in Neuroscience Companies, Small-Cap Player NMTC is Gaining Speed….   Greetings Investors,   Arguably one of the hottest topics in biotech in recent years has been Biogen's (NASDAQ: BIIB) groundbreaking Alzheimer's treatment aducanumab.   It is currently under review by the FDA for approval and if it is approved, would be the first-ever drug to slow the progression of this killer disease. This only highlights the growing need for developments in neuroscience that target neurological disorders.   With the growing epidemic of neurological disorders from Epilepsy to Parkinson's Disease, and even chronic back pain and depression… it has become apparent to pay close attention to the companies tackling such disorders!   NeuroOne Medical Technologies Corp. (NASDAQ: NMTC) is an emerging and exciting player on the NASDAQ that is doing exactly just this!   How is this essentially undiscovered company potentially about to revolutionize healthcare? NMTC has developed a breakthrough thin-film electrode.   The company is focused on treating Epilepsy, Parkinson's Disease, chronic back pain from failed surgeries, dystonia, and many other related neurological disorders.   Thanks to strategic partnerships with the Mayo Clinic and Zimmer Biomet (NYSE:ZBH, ~$22B+ Mkt Cap), the company anticipates that their technologies will be widely adopted in the near future.   You know when the Mayo Clinic gets involved… it means something. Trading at under $3.00 makes NMTC a growth story in the biotech space to keep your eyes on!       https://n1mtc.com/ NeuroOne Medical Technologies Corp. NASDAQ: NMTC Advancing Neuroscience! "Neuroscience is the next great frontier in medicine. I think we're on the cusp of some major breakthroughs in this space." -        Casper Hoogenraad, Genentech (VP, Neuroscience) June 2021 \ NMTC is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs.  HIGHLIGHTS: -       Highly disruptive – step change technology improvement -       Platform technology with broad diagnostic and therapeutic applications -       Strategic partnerships with Zimmer Biomet and Mayo Clinic     Technology Value Proposition   We think, feel, move and sense through a web of 80+ billion neurons in the brain which communicate through electrical signals.   Electrodes are used to detect, record and monitor neurological activity and stimulate or ablate tissue to regulate brain activity.     NMTC is developing and perfecting high-definition, minimally invasive Evo® Cortical Electrodes for the diagnosis and treatment of various neurological conditions.    Why should this breakthrough company be on your watchlist?   First, there is substantial market opportunity. Second, these are disruptive patented technologies. Third, the technology addresses a significant and unmet need and there could be substantially improved outcomes.   AND… these are already FDA cleared electrodes!       In November of 2019, NMTC had received 510(k) clearance for Evo Cortical Electrode technology for temporary (less than 30 days) recording, monitoring, and stimulation on the surface of the brain!   "On August 9th we re-submitted to the FDA a special 510(k) seeking clearance for <30 day use. In addition, we were excited to have the first Evo sEEG case performed by Dr. Robert Gross of Emory University for less than 24 hour use." -       Dave Rosa, CEO of NeuroOne   BRIDGING THE GAP – ARTIFICIAL INTELLIGENCE   § Damaged neurons can cause a break in neuron-to-neuron connectivity: etiology for many neurological disorders. § Successful treatments achieved by implanting small wires to record and reintroduce the natural signal. § Elon Musk and others have started companies to try to implant millions of wires in the brain. § NeuroOne's high-definition thin film platform could allow for recording and stimulation of the neurons to bridge these gaps more effectively. § NeuroOne technology is scalable allowing thousands of contacts to be implanted.     Zimmerman Development Agreement   Zimmer Biomet, one of the world's most highly respected medical device manufacturers!   -       Zimmer to exclusively commercialize and distribute NMTC's Evo ® electrode technology -       Agreement signed in July 2020, $2 million upfront payment with additional milestones -       Zimmer is a worldwide leader in robotic technology used in minimally invasive neurosurgeries -       Evo® electrode product line complementary to Zimmer's ROSA ONE® Brain platform -       Partnership enables efficient deployment into the market -       Allows NeuroOne to focus on development and pursue additional applications for technology Development and Distribution Agreement with Zimmer Biomet, one of the world's most highly respected medical device manufacturers     Zimmer Biomet agreed to an accelerated $3.5M milestone payment for the Evo® sEEG electrode. This amendment to our agreement provides NeuroOne with near term capital without the need for a highly dilutive financing and reinforces their ongoing partnership with Zimmer Biomet."   MAYO CLINIC PARTNERSHIP   -       Mayo Clinic began testing technology in pre-clinical models and clinical research in 2015 -        Mayo Clinic leading neurologist, Dr. Worrell, chairs the NeuroOne Scientific Advisory Board -       First commercial human use of Evo® Cortical Electrodes performed at Mayo Clinic in November 2020 Mayo Clinic partnership with NeuroOne began in 2017     DEVELOPMENTS   NMTC announced that it has successfully completed initial pre-clinical long-term testing of recording capabilities on its platform thin film electrode technology.   In test procedures, the electrodes' ability to record electrical activity over a span of 5 years was measured using an accelerated aging test model.   The test results demonstrated NMTC's thin film electrodes' reliability against environmental factors that may contribute to device failure or malfunction, which is a well-established challenge with thin film electrode technology.   NMTC is also advancing a pipeline of therapeutic electrode technologies for brain tissue ablation, chronic stimulation use for DBS (deep brain stimulation) and spinal cord stimulation for chronic back pain.     The Company believes these therapeutic electrode technologies are targeted to addressable markets of over $10 billion!   NMTC expects to release long-term data in the near future…   Q3 Milestones   ·       Completed ablation system prototypes, including RF generator from RBC Medical and NeuroOne's electrodes and accessories, ahead of schedule and successfully tested the first fully integrated sEEG/RF ablation system. ·       Achieved major milestone with first sEEG electrode case for intraoperative brain mapping at the subsurface level of the brain performed at Emory University. ·       Qualified second source for manufacturing for both the Evo cortical and sEEG electrodes. ·       Completed validation and placed orders for a new cable assembly which will provide significant cost reduction. ·       Established advisory board of leading anesthesiologists and neurosurgeons for spinal cord stimulation program. ·       Completed design verification to extend shelf life for Evo cortical electrodes to three years. ·       Presented at the HC Wainwright Global Investment Conference and the NobleCon 18 Investor Conference. ·       Exhibited the Evo Cortical electrode family in partnership with Zimmer Biomet at the American Association of Neurological Surgeons Annual Scientific Meeting and the American Society for Stereotactic and Functional Neurosurgery Biennial Meeting. ·       The first peered-reviewed paper presenting the biocompatibility results for NeuroOne subdural thin film electrodes was  published in the Frontiers of Neuroscience journal on April 29, 2022. ·       The Company's Evo sEEG implantation accuracy study was accepted as a podium presentation at the Biennial Meeting of the World Society for Stereotactic & Functional Neurosurgery, to be held in South Korea September 4-7 2022. Upcoming Targeted Milestones ·       Evo sEEG Depth Diagnostic Electrode ·       OneRF(RF ablation system) ·       Partner with a research organization to develop electrode for new clinical indication. ·       Chronic Use Electrode The Bottom Line According to Global Market Insights, today there is a massive $13.6 billion neurostimulation devices market developing for the ongoing study of the vast arrays of the brain's neural connections.    The diagnostic electrode technology currently used to detect neurological disorders is the same that was developed way back in the 1960s.   NMTC is truly not just any medtech company…   Not when both Evo Cortical and sEEG Electrodes are BOTH FDA approved!   Both the Mayo and Cleveland Clinic have conducted preclinical studies, which have produced promising results utilizing the company's devices in humans and/or animals.   Zimmer Biomet commercial launch was initiated just last year!   All of this reads like a recipe for success and NMTC may beone of the most exciting narratives to emerge on the NASDAQ!   PLUS, the company has cash on hand at $10.2M as of June 30th and NO DEBT OUTSTANDING! Start your research right away!     This communication includes advertising material and PAID ADVERTISEMENTS provided to our subscribers.   Copyright 2022 © TopStockTips.com is owned and operated by the owner of CareBear Marketing Group LLC. Disclaimer and Privacy For more Information please contact Support@TopStockTips.com This website provides information about the stock market and other investments. This website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This website is for informational purposes only. The Author of this website is not a registered investment advisor and does not offer investment advice. You, the reader, bear responsibility for your own investment decisions and should seek the advice of a qualified securities professional before making any investment. Nothing on this website should be considered personalized financial advice. Any investments recommended here in should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security.   CareBear Marketing Group, its managers, its employees, affiliates, and assigns (collectively "The Company") do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above. To the maximum extent permitted by law, the Company disclaims all liability in the event any information, commentary, analysis, opinions, advice and/or recommendations provided herein prove to be inaccurate, incomplete, or unreliable, or result in any investment or other losses. You received this message as part of your subscription to TST. TST is a free financial news and information website. We do not directly sell any products or offer any personal financial advice, nor do we advocate the purchase or sale of any security or investment for any specific individual. We also do not make any guarantee or warranty about what is advertised above. If you have questions or concerns about a product you've seen in one of our emails, we encourage you to reach out to that company directly.   Disclaimer – Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated, and edited by CareBear Marketing Group. Any wording found in this e-mail or disclaimer referencing to "I" or "we" or "our" or "TST" refers to CareBear Marketing Group. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore unqualified to give investment recommendations. Companies with low prices per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold our site, its editor's, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares, we will list the information relevant to the stock and the number of shares here. We do not own any shares in NMTC. We have been currently compensated up to Seventy-Five Thousand Dollars Cash ($75,000) via bank wire transfer from a third-party Legends Media for a 3 Day Marketing Program regarding NMTC with a start date of 8/29/2022 to 8/31/2022. TST's business model is to receive financial compensation to promote public companies. This compensation is a major conflict of interest in our ability to be unbiased regarding our alerts. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company's website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, TST often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers' works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer's communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.

, Rua Frei Tome de Jesus N18 1Dto, 1700-215, Lisboa, Portugal You may unsubscribe or change your contact details at any time.

Powered by: